Loading
A phase 1/2 trial of SRN-101 run by Siren Biotechnology, not yet recruiting.
A Study of SRN-101 Gene Therapy in Adults With Recurrent High-Grade Glioma (ALERT-1) is a phase 1/2 interventional study registered as NCT07902037 by Siren Biotechnology, with 40 participants planned, started 2026-12. Conditions recorded: Recurrent High Grade Gliomas, Glioblastoma (GBM), Astrocytoma, Oligodendroglioma and Diffuse Hemispheric Glioma. Interventions recorded: SRN-101.
Shares SRN-101, Siren Biotechnology, Brain and spinal cord tumours (all types) and the tag pipeline.
Shares Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, Glioma & glioblastoma and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/